Literature DB >> 2036657

Effect of culture media on lymphokine-activated killer effector phenotype and lytic capacity.

D M Finkelstein1, R G Miller.   

Abstract

We compared the ability of murine lymphokine-activated killer (LAK) cells grown in either a serum-supplemented "standard" medium (alpha MEM plus fetal calf serum) or a serum-free medium (AIM-V) to lyse a range of tumour targets. LAK cells grown in either of the media killed a cultured murine tumour line (YAC-1 lymphoma) well and spared syngeneic "self" cells (concanavalin-A-stimulated splenocytes). However, a striking difference was noted in the ability of LAK cells grown in alpha MEM plus fetal calf serum (as opposed to AIM-V) to kill "modified self" cells (trinitrophenol-modified concanavalin A blasts); LAK cells grown in the former always killed modified self cells better than those grown in the latter. This pattern held under a broad range of experimental manipulations and was found to be related to a relative increase in CD3-bearing LAK cells grown in the standard medium. These data suggest that the two media cannot be used interchangeably. This conclusion may have clinical implications for the use of LAK cells, as animal studies have been done using LAK cells generated in serum-containing medium and clinical studies have used LAK cells generated in serum-free medium.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2036657     DOI: 10.1007/bf01742537

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

1.  Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations.

Authors:  Z K Ballas; W Rasmussen
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

Review 2.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

3.  Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects.

Authors:  L G Thijs; C E Hack; R J Strack van Schijndel; J H Nuijens; G J Wolbink; A J Eerenberg-Belmer; H Van der Vall; J Wagstaff
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

4.  IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis.

Authors:  D Jablons; E Bolton; S Mertins; M Rubin; P Pizzo; S A Rosenberg; M T Lotze
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

5.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

Authors:  M Rosenstein; I Yron; Y Kaufmann; S A Rosenberg
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

Review 6.  Development of new immunologic approaches to cancer therapy.

Authors:  S A Rosenberg
Journal:  Blood Purif       Date:  1988       Impact factor: 2.614

7.  Induction of lymphokine activated killer cells in serum-free medium.

Authors:  C J Froelich; S Guiffaut
Journal:  J Immunol Methods       Date:  1986-02-12       Impact factor: 2.303

8.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Authors:  J J Mulé; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

9.  Studies of serum-free culture medium in the generation of lymphokine activated killer cells.

Authors:  L M Muul; K Nason-Burchenal; C Hyatt; S Schwarz; D Slavin; E P Director; S A Rosenberg
Journal:  J Immunol Methods       Date:  1987-12-24       Impact factor: 2.303

10.  Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulations.

Authors:  Z K Ballas; W Rasmussen; J K van Otegham
Journal:  J Immunol       Date:  1987-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.